Erdafitinib is not on the market in China, and patient access methods are being discussed

Erdafitinib (Erdafitinib), as a new type of targeted therapy, has significant efficacy in cancer patients carrying FGFR gene mutations and has been widely recognized internationally. However, erdafitinib has not yet been officially launched in China, which poses challenges to Chinese patients who are in urgent need of treatment with this drug. So, faced with this situation, how should Chinese patients obtain erdafitinib?

One possible way is to purchase erdafitinib through overseas medical institutions or professional overseas medical consulting companies. These institutions usually have close cooperative relationships with foreign pharmaceutical factories or medical institutions and can provide patients with formal drug purchase channels. Patients only need to provide the necessary medical certificates and prescriptions to purchase erdafitinib through these institutions. However, during this process, patients need to carefully choose the institution to ensure that it is formal and reputable to ensure the authenticity and safety of the drugs.

Another way is to consider relatives and friends purchasing on your behalf. If the patient has relatives or friends living or working abroad, they may be able to assist the patient in purchasing erdafitinib locally and bringing it back home. This method is relatively economical, but patients need to ensure the reliability of purchasing channels and the authenticity of the drugs to avoid purchasing fake and shoddy products.

In addition, with the gradual relaxation of policies and the advancement of medical technology, Chinese patients are expected to have more ways to obtain erdafitinib. For example, some policies allow drugs that are urgently needed clinically and have been marketed in Hong Kong and Macao to enter the mainland market under certain conditions, which provides patients with more choices. At the same time, medical institutions may also provide patients with unmarketed drugs such as erdafitinib through clinical trials or compassionate use applications.

Finally, it needs to be emphasized that no matter how patients obtain erdafitinib, they should use the drug rationally under the guidance of a doctor and pay close attention to the treatment effects and adverse reactions. At the same time, patients should maintain a positive attitude and believe that with the continuous development of medical technology and the gradual improvement of policies, advanced drugs such as erdafitinib will be able to benefit Chinese patients faster and more widely.